http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
성도환(Do Hwan Seong) 대한비뇨기종양학회 2011 대한비뇨기종양학회지 Vol.9 No.2
Androgen deprivation therapy (ADT) is the mainstay of systemic therapy for advanced or metastatic prostate cancer. The majority of 90% of patients respond to currently available first line ADT therapy. However, responses are transient and metastatic disease progresses as castration-resistant prostate cancer (CRPC). Traditional secondary hormonal manipulations can be of clinical benefit in some patients after primary ADT failure. Novel therapies for CRPC have demonstrated promising activity in many men with CRPC and may redefine the clinical management of these patients. This paper summarises the current clinical development of these agents as well as a brief review of hormonal strategies in CRPC.